Table 1.
—Characteristics of the Study Subjects
| Characteristic | IPT Group (n = 39) | Observation Group (n = 39) | All Subjects (N = 78) |
| Age, y | 26.3 ± 6.3 | 26.9 ± 6.3 | 26.6 ± 6.4 |
| Male sex | 12 (31) | 13 (33) | 25 (32) |
| Weight, kg | 69.8 ± 16.1 | 70.8 ± 17.1 | 70.3 ± 16.5 |
| BMI, kg/m2 | 26.0 ± 6.6 | 26.1 ± 6.3 | 26.1 ± 6.4 |
| Hemoglobin, g/dL | 14.2 ± 1.2 | 14.1 ± 1.3 | 14.2 ± 1.3 |
| Tuberculin skin test, mm induration | 19 (17-23) | 19 (17-22) | 19 (17-22) |
| Baseline QFT-GIT, IU/mL | 10.0 (5.8-10.0) | 10.0 (1.9-10.0) | 10.0 (2.5-10.0) |
| QFT-GIT at end of IPT or observation, IU/mL | 5.2 (1.7-10.0) | 4.9 (1.1-10.0) | 5.1 (1.4-10.0) |
Data are presented as mean ± SD, No. (%), or median (interquartile range). IPT = isoniazid preventive therapy; QFT-GIT = QuantiFERON-TB Gold In-Tube.